Clinical-stage oncology company, PharmaAust Ltd (ASX: PAA) has announced the appointment of Mr. Colin La Galia as new Chief Executive for its wholly-owned subsidiary – Epichem.
Who is Mr. Colin?
- Colin is a highly experienced executive in phamaceuticals, devices and diagnostics, who was previously the Regional Business Director and Commercial Head of Asia Pacific, China and Japan for Abbott Rapid Diagnostics;
- Colin has held senior roles for over 20 years at various big firms like Alere Inc, Origin Healthcare, Hollywood Fertility Centre, GlaxoSmithKline and Merck Sharpe & Dohme.
By 01:04 PM AEST, PAA was trading at $0.13, up by 4% relative to the last close.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.